Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients
| العنوان: | Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients |
|---|---|
| المؤلفون: | Asunción Martin Ruiz-Valdepeñas, Mariano Provencio, Fernando Franco, Paloma Martín, Juan Luis Cruz-Bermúdez, Alberto Cruz-Bermúdez, Virginia Calvo, Aránzazu García-Grande, Atocha Romero, María José Coronado, Margarita Sánchez-Beato, Lourdes Gutiérrez, Maria Torrente, David Pérez-Callejo |
| المساهمون: | UAM. Departamento de Medicina |
| المصدر: | Oncotarget Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid Biblos-e Archivo. Repositorio Institucional de la UAM instname |
| بيانات النشر: | Impact Journals, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, ALK inhibitors, medicine.medical_specialty, Medicina, Concordance, medicine.medical_treatment, circulating tumor cells, 03 medical and health sciences, 0302 clinical medicine, Circulating tumor cell, Internal medicine, hemic and lymphatic diseases, medicine, Anaplastic lymphoma kinase, Liquid biopsy, Lung cancer, liquid biopsy, business.industry, Circulating tumor cells, medicine.disease, ALK-rearrangement, 3. Good health, Surgery, respiratory tract diseases, Radiation therapy, 030104 developmental biology, non-small-cell lung cancer, 030220 oncology & carcinogenesis, Adenocarcinoma, business, Non-small-cell lung cancer, Biomedical sciences, Research Paper |
| الوصف: | Background: The identification of anaplastic lymphoma kinase (ALK) rearrangements is found in approximately 5% of non-small-cell lung cancers (NSCLCs). However, the development of liquid biopsies as a diagnostic tool is less developed in these cases. This study investigates the use of CTCs during treatment, together with an extended follow-up to correlate with clinical evolution. Patients and Methods: A total of 13 patients out of a cohort of 212 patients with lung adenocarcinoma, presented ALK rearrangements (6%) confirmed by tumor biopsy. A total of 60 serial blood samples were collected from these patients who were prospectively enrolled in the study. Results: All patients had a positive CTC count at baseline (mean = 3). The median follow-up was 9 months (range 1-17 months). Three patients underwent surgery and their CTC counts decreased after the procedure but still remained detectable. After radiotherapy, 3 cases showed an average decrease of 5 CTCs. A total of 6 patients were treated with ALK inhibitors and a partial response was observed in 3 of them, who also presented decreased CTC counts. The other 3 patients presented primary resistance, and their CTC counts were higher than those obtained prior to progression. Conclusion: We believe that the use of CTCs for dynamic monitoring of NSCLC with ALK rearrangement and to detect disease persistence or recurrence may be a reliable technique. CTC counts may also have potential use to monitor the efficacy of ALK inhibitors, facilitating detection of resistance to treatment This study was supported by Carlos III Institute of Health, Spanish Ministry of Science and Innovation, and European Regional Development Fund (grant number: PI16/01818 and PIE14/00064), D. Pérez-Callejo is supported by SEOM-Río-Hortega contract, A Romero is supported by Joan Rodés fellowship (grant number: JR14/00017) and M Sánchez-Beato is supported by Miguel Servet contract (CP11/00018 and CPII16/00024) |
| وصف الملف: | application/pdf |
| اللغة: | English |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fda8ff3eb5ddece29d1c9af44ce11cb https://hdl.handle.net/10486/681151 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....9fda8ff3eb5ddece29d1c9af44ce11cb |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |